TCGA-BH-A8FY-01A-11R-A36F-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 10
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.290
- XENOBIOTIC_METABOLISM+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.220
- BILE_ACID_METABOLISM+0.210
- DNA_REPAIR+0.170
- FATTY_ACID_METABOLISM+0.170
- ESTROGEN_RESPONSE_LATE+0.160
- COAGULATION+0.130
- PANCREAS_BETA_CELLS+0.130
- ESTROGEN_RESPONSE_EARLY+0.110
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.580
- INTERFERON_GAMMA_RESPONSE-0.470
- INTERFERON_ALPHA_RESPONSE-0.410
- ALLOGRAFT_REJECTION-0.400
- TGF_BETA_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.390
- MITOTIC_SPINDLE-0.380
- G2M_CHECKPOINT-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- APICAL_SURFACE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-YF-AA3L-01A-11R-A38B-07 | — | — | 0.921 |
| 2 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.899 |
| 3 | TCGA-AC-A3YJ-01A-11R-A22U-07 | — | B | 0.883 |
| 4 | TCGA-55-6972-01A-11R-1949-07 | — | cohortA2 | 0.878 |
| 5 | TCGA-BH-A0HN-01A-11R-A10U-07 | — | B | 0.870 |
| 6 | TCGA-CF-A47W-01A-11R-A23W-07 | — | — | 0.865 |
| 7 | TCGA-55-A492-01A-11R-A24H-07 | — | cohortA2 | 0.858 |
| 8 | TCGA-E2-A1B4-01A-11R-A12P-07 | — | B | 0.856 |
| 9 | MDT-AP-0349 | Med | Medulloblastoma | 0.856 |
| 10 | TCGA-CF-A5U8-01A-11R-A28M-07 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |